Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in ...

Figure 2: The algorithm used for the screening of patients on the waiting list for orthotopic liver transplantation and the therapeutic decisions made thereafter. Although no peroperative deaths ...

Silexion Therapeutics Corp. has completed its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. SIL-204 is a next-generation siRNA candidate designed to target a broad range of ...

This study is the first systematic evaluation of SIL-204 administered subcutaneously in orthotopic pancreatic cancer models, focusing on its ability to reduce primary tumor growth and metastatic ...

Silexion Therapeutics (SLXN) announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This ...

Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in Coming Weeks Grand Cayman, ...

SIL-204's ability to reduce primary tumor growth when administered systemically in orthotopic pancreatic cancer models, where human tumor cells are implanted directly into the pancreas SIL-204's ...